Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Universal Biosensors (UBI) has entered into an agreement with Singularity SpA for the distribution of its wine testing platform device in Chile
  • Sentia is UBI’s newest product, a wine testing platform which is set to launch globally
  • The agreement for the distribution of Sentia is for a three-year term and contains standard renewal and termination options available to both parties
  • The agreement includes an initial commitment to purchase Sentia devices and strips, which will be delivered to Singularity over the course of the next few weeks
  • Universal Biosensors shares are up 5.15 per cent, trading at 71.5 cents

Universal Biosensors (UBI) has entered into a non-exclusive agreement with Singularity SpA to distribute its wine testing platform device in Chile.

The agreement for the distribution of Sentia is for a three-year term and contains standard renewal and termination options available to both parties.

Universal Biosensors specialises in the design and development of electrochemical cells used in conjunction with point-of-use devices, used in industries like healthcare, food and wine. Sentia is UBI’s newest product, a wine testing platform which is set to launch globally.

“The launch of Sentia into Chile is another positive step in the commercialisation of Sentia globally,” said CEO of UBI John Sharman.

“Chile is the eighth largest wine producing country in the world and Singularity is part of a leading group with diverse expertise in point-of-use devices with connections across Chile’s 200,000 hectares of vineyards.”

“We believe the possibility of Sentia’s future testing capability for glucose, fructose, malic acid and others will add significant value to the winemaking industry.

“We are negotiating terms with a number of key industry players around the world and look forward to reporting additional distribution partnerships in due course.”

The agreement includes an initial commitment to purchase Sentia devices and strips, which will be delivered to Singularity over the course of the next few weeks.

Universal Biosensors shares are up 5.15 per cent, trading at 71.5 cents at 1:00 pm AEST.

UBI by the numbers
More From The Market Herald
Advanced Human Imaging (ASX:AHI) - CEO and Chairman, Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) enters Estonian market

Advanced Human Imaging (ASX:AHI) has entered the Estonian market after signing a binding term sheet with…

" Chimeric Therapeutics (ASX:CHM) receives US patent for CLTX CAR technology

Chimeric Therapeutics (ASX:CHM) has received a US patent for certain applications of its CAR T therapy.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo Diagnostics (ASX:AT1) receives COVID-19 rapid antigen test approval in NZ

Atomo Diagnostics (ASX:AT1) receives COVID-19 rapid antigen test approval in New Zealand

" Telix Pharmaceutical (ASX:TLX) first patient dosed in prostate cancer therapy program

Telix Pharmaceuticals Limited (ASX:TLX) has first patient dosed in its prostate-specific membrane antigen.